GLP-1 myths — what patients actually need to know.

Few medications have entered public consciousness as quickly as the GLP-1 receptor agonists — semaglutide and tirzepatide, sold under names like Ozempic, Wegovy, Mounjaro, and Zepbound. The mechanism is real. The weight loss is real. The pace of the discourse is the problem. In a clinical practice, we spend a meaningful portion of every weight-management consult correcting things patients have absorbed from social media, op-eds, and word of mouth.

Here is a measured version of what we actually tell patients.

Myth: They are just an appetite suppressant.

GLP-1 agonists do reduce appetite, but the mechanism is more layered than that. They slow gastric emptying, which contributes to early satiety. They modulate insulin and glucagon signaling, which matters substantially for metabolic syndrome. They appear to act on central reward pathways that drive food cravings in ways that no prior generation of weight-loss medication touched directly. Calling them "appetite suppressants" undersells what they do — and obscures why they work for patients who have failed every prior intervention.

Myth: You can just stop taking them when you reach goal weight.

This is one of the most common patient misconceptions and one of the most clinically consequential. The available evidence indicates that most patients regain a substantial portion of the lost weight after discontinuing the medication, because the underlying physiology that drove the weight in the first place did not disappear. Patients who plan for the medication to be a short-term tool to a lifelong destination often arrive disappointed.

That does not mean every patient must stay on a GLP-1 indefinitely. It does mean the off-ramp must be planned, slow, and supported — typically with a combination of dietary protocol consolidation, lifestyle medicine reinforcement, and sometimes a different long-term agent. Patients who do not have this plan in place are the ones who regain.

Myth: Side effects are mild and short-lived.

GI side effects — nausea, vomiting, reflux, constipation, diarrhea — are common and dose-dependent. For most patients they are manageable with slow titration and proactive symptomatic care. For some patients they are severe enough to require dose reduction or discontinuation. Risks of pancreatitis, gallbladder disease, and gastroparesis are real, even if uncommon, and warrant honest counseling. The framing some clinics use that side effects are universally mild is wrong, and patients who have been told that often feel betrayed when their experience differs.

Myth: They are dangerous and unstudied.

These medications have more clinical-trial data behind them than most prescription drugs in everyday use. The conversation is loud; the evidence base is unusually substantial.

The opposite myth, repeated in the other direction, is also wrong. The GLP-1 receptor agonist class has more high-quality clinical trial data behind it than most medications in everyday clinical use. Cardiovascular outcome trials have been positive — semaglutide reduces major cardiovascular events in patients with diabetes and elevated risk. Kidney protection is documented. Weight loss is consistently in the 15-20% range for tirzepatide at higher doses, which is the territory previously reserved for bariatric surgery. These are not unstudied drugs. The conversation is loud; the evidence base is unusually substantial.

Myth: They are interchangeable.

Semaglutide, liraglutide, and tirzepatide are not the same drug. Tirzepatide has dual agonism at the GLP-1 and GIP receptors and produces, on average, more weight loss than pure GLP-1 agonists in head-to-head data. Patients who do not respond well to one molecule sometimes respond well to another. Compounded versions and grey-market sources further muddy the picture and carry real safety concerns. Drug selection is part of the clinical work, not a brand-name shopping list.

Myth: Compounded versions are the same as branded.

The pharmacy landscape is complicated by the rise of compounded semaglutide and tirzepatide, often marketed at lower cost. Compounded versions are not generic equivalents of the branded medications. They are made by compounding pharmacies under different regulatory frameworks, with variable concentrations, sourcing, and quality control. Some are produced by reputable 503A and 503B facilities under physician supervision; others are produced by grey-market actors whose product fidelity is genuinely unknown. The clinical implication is straightforward: source matters, the supervising physician matters, and the "same molecule, lower price" framing is not always accurate at the dose patients actually receive.

What we actually do

Our weight management program treats GLP-1 medications as one tool within a coordinated program — not as the program itself. The first conversation is always a medical evaluation: history, labs, weight trajectory, metabolic picture, prior interventions, and an honest discussion of what each tool can and cannot do.

Members who are appropriate candidates and choose to start on a GLP-1 receive a structured titration with proactive side-effect management, plant-forward dietary support through the registered dietitian, and the kind of follow-up cadence that is genuinely supportive. Weekly check-ins, dose escalation reviews, and refill coordination run through the clinical team — so the medicine and the relationship stay in the same hands.

Some patients use medication as a bridge to durable lifestyle change. Some are not good candidates and we say so. The medicine is responsive, not prescriptive.